Temenos Announces Infinity Digital for Salesforce to Combine Enhanced Customer Engagement With Industry Leading Banking Platform
Temenos (SIX: TEMN), the banking software company, today announced the availability of Infinity Digital for Salesforce that brings together the worlds of CRM, assisted channels and digital channels onto a single platform, available here on Salesforce AppExchange – the world’s leading enterprise cloud marketplace.
This solution integrates Salesforce Financial Services Cloud with Temenos’ digital banking platform, giving customer-facing teams in banks a holistic view of their customers surfacing both customer engagement and transactional banking data across all channels and transactional systems.
Infinity Digital for Salesforce offers banks synchronization between Salesforce Financial Services Cloud and the bank’s core banking systems. It helps banks achieve higher efficiency and streamlining of servicing, onboarding and origination processes with better personalization and greater customer experience.
The banking industry has fundamentally changed in recent years; business models are dramatically reshaped, as customers demand higher personalization of services regardless of their chosen method of interaction. Banks need visibility of customer behavior and transactional footprint across touchpoints in an omnichannel way and a consistent approach to delivering high-impact customer journeys.
Infinity Digital for Salesforce enables banks to better serve their customers with highly tailored offers made possible through relevant, complete and accurate information at every interaction. Banks can now integrate digital and assisted channels with their transactional system and create a unified platform across marketing, sales, servicing and origination functions to give client-facing teams – from branch and contact center staff to relationship managers and chat operators – a truly complete, actionable view of customer interactions.
Infinity Digital for Salesforce offers out-of-the box synchronization between Salesforce Financial Services Cloud and the bank’s core banking system, be it either Temenos or other third party system. The solution provides a 360-customer view enhanced with real-time current balances and latest transactions as well as all other customer interactions, giving client-facing teams a holistic and fully informed view of customer activities and product portfolio.
With the solution now available for retail banking, and more capabilities planned in the future to cover business banking and wealth management.
Max Chuard, Chief Executive Officer, Temenos said: "We are excited to extend our leadership in digital by combining our open, banking platform with Salesforce Financial Services Cloud in a single platform to help banks reinvent the customer and employee omnichannel experience. We are aiming to solve one of the most fundamental problems in banking today by connecting the worlds of CRM, transactional footprint and digital interactions. This go-to-market strategy will accelerate our penetration in the digital front office segment. We help banks with complex channel architectures by breaking down silos to reduce complexity and costs, and achieve customer-centric business transformation to provide outstanding customer experiences.”
“We’re excited to see Temenos innovate with Salesforce Financial Services Cloud to help banks deepen their relationships with customers through hyper-personalized experiences,” said Eran Agrios, SVP & GM, Financial Services, Salesforce. With Infinity Digital for Salesforce, customers can connect their core banking systems to their omni-channel experiences, delivering hyper-personalized experiences faster.
The product offers:
● Enriched 360-customer view that unlocks the full potential of the core banking system. The new solution shows the financial products the customer owns in the bank and outside the bank through open banking account aggregation services, ensuring that the shown balance and latest transactions exactly reflect what the core banking system stores.
● Unified digital, human-assisted, and high-touch channels that give insights into customer digital activity and provide a real omnichannel approach to customer onboarding and product origination. This means that a customer could start a journey in an assisted channel, continue it through a self-service channel and finalize in any other channel.
● Consistency between the CRM and the core banking system by ensuring that only after an origination process has been approved and the product fulfilment is completed, the opportunities could be closed as won.
● Integration of the most common servicing actions such as bill pay, fund transfers, loan payments and direct debits with Salesforce Financial Services Cloud to provide comprehensive servicing capabilities to customer facing employees on a single application.
– Ends –
Temenos AG (SIX: TEMN) is the world's leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks' IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com
About Salesforce AppExchange
Salesforce AppExchange, the world’s leading enterprise cloud marketplace, empowers companies, developers and entrepreneurs to build, market and grow in entirely new ways. With more than 6,000 listings, 10 million customer installs and 117,000 peer reviews, AppExchange connects customers of all sizes and across industries to ready-to-install or customizable apps and Salesforce-certified consultants to solve any business challenge.
● Like Salesforce on Facebook: http://www.facebook.com/salesforce
● Follow Salesforce on Twitter: https://twitter.com/salesforce
● Follow Temenos: https://www.linkedin.com/company/temenos
● Follow Temenos on Twitter: https://twitter.com/Temenos
Salesforce, AppExchange, Financial Services Cloud and others are among the trademarks of salesforce.com, inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination
Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib
New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release
Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet
Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release
On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan
Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release
Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of